Helping to accelerate the development of novel drugs against Covid-19 disease
Thus, the current fight against Covid-19 disease heavily relies on already available drugs. Unfortunately, there is hardly any drug that fights the disease effectively. Cortisone based therapeutics are currently the ones used most frequently and most successfully. The originally promising drug Remdesivir, which has been approved for the treatment of Covid-19 for several months ago, plays a limited role in treatment, because it only works during the early phase of the disease. Therefore, there is still a high demand in developing new drugs against Covid-19 disease.
myriamed can help to accelerate the development of these drugs. With its products and services myriamed supports pharmaceutical and biotech companies from early preclinical to clinical stages of drug development to accelerate the clinical translation of novel safe and efficacious therapeutics.
myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in the controlling of their fate as to the differentiation into defined cellular lineages and tissues (published for example in Tiburcy et al. 2017 and Long et al. 2018). The myriamed product portfolio is constantly evolving and based on a comprehensive IP portfolio to offer its know-how and associated services in drug development.
To learn more about myriamed’s products and services please contact us on:
Tel.: +49 551 28878-170
myriamed – the drug development accelerator
Separating the pharmacological wheat from the chaff is the primary goal of myriamed. Our proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. Our platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.
The availability of human cell and tissue models is transforming preclinical drug development. Applications range from early stages of lead discovery to advanced individualized phenotypic screens to shape a promising therapeutic candidate. myriamed offers a broad portfolio of highly standardized services as well as custom-made solutions to accelerate drug development.
At myriamed we focus on heart and skeletal muscle as well as on neuronal organoids. Our myrCell and myrTissue platforms define wanted and unwanted drug effects in a unique human context. myrScreen combines our expertise in phenotypic drug screens and enables deep phenotyping of drug effects on healthy or diseased human heart and skeletal muscle as well as on neuronal organoids.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Helping to accelerate the development of novel drugs against Covid-19 disease here
News-ID: 2201464 • Views: 357
More Releases from myriamed GmbH
myriamed launches online shop
To deliver the best possible service to our customers, myriamed has launched its own online shop. The shop features various human iPSC derived cell types (myrCell) such as cardiomyocytes, skeletal muscle cells and stroma cells as well as various tissue types (myrTissue) such as cardiac tissue, fibrotic tissue or brain organoids. In addition, you can order our proprietary tissue culture plates (myrPlates) via the shop to cast and culture macroscale
myriamed is a member of the international 4D Bioprinting network
myriamed has become a member of the ZIM innovation network 4D Bioprinting. The network, which is led by EurA AG supports concrete innovative products and new services in the field of bioprinting for applications in biology, pharmacy, and medicine. Thus, the network promotes the commercialization of the innovative technologies of the network partners by market-oriented R&D projects and establishment of new value chains for biopharmaceuticals and medicine. Phase 1 of the
myriamed has joined Science Exchange
Science Exchange, the leading SaaS-enabled marketplace platform for outsourced R&D services, has partnered with myriamed. Visit myriamed’s profile to inquire about our services or request a quote. There are no additional contracts required if you request on Science Exchange and you can order immediately. Please visit our profile here: http://bit.ly/myriamed_Science_Exchange About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and
myriamed is now a member of the Network for Pharma Solutions
We are proud to announce that myriamed is now a member of the Network for Pharma Solutions (NetPhaSol). NetPhaSol is a cooperation network focusing on drug discovery & development. It serves as a platform for research, development and marketing of new products, technologies and services in drug development. About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in